الأشعة

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. A Study to Assess Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH)

   Rochester, Minn.

   The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

4. A Study to Review Magnetic Resonance Imaging in Patients with Epilepsy

   Rochester, Minn.

   The primary purpose of this study is to compare the diagnostic utility of 7T MRI versus 3T MRI in the detection of subtle epileptogenic lesions in the brain.

6. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients

   Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients.

10. Detection of Vascular and Inflammatory Plasma Biomarkers in Patients Diagnosed with Obstructive Sleep Apnea and MRI-defined Cerebral Small Vessel Disease

    Jacksonville, Fla.

    The purpose of this study is to evaluate plasma biomarkers of vascular function and inflammation in patients with newly-diagnosed Obstructive Sleep Apnea (OSA) and pre-existing imaging evidence of Cerebral Small Vessel Disease (CSVD).

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. A Clinical Use Application for the Humanitarian Use Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Primary or Secondary Liver Neoplasia

   Eau Claire, Wis.

   This protocol allows multiple treatments with TheraSphere® that may be delivered on an outpatient basis. Patients may receive a single dose to a liver lobe or segmental treatment delivered as a sequence of treatments approximately 30-90 days apart. The principal clinician, working with a multidisciplinary team, will develop a specific treatment plan for each patient, based upon the presenting condition of the patient, the vascular anatomy and the desired goal of treatment.

4. A Study to Review Magnetic Resonance Imaging in Patients with Epilepsy

   Rochester, Minn.

   The primary purpose of this study is to compare the diagnostic utility of 7T MRI versus 3T MRI in the detection of subtle epileptogenic lesions in the brain.

7. Assessment of the Mechanical Properties of Lung Parenchyma using Magnetic Resonance Elastography

   Rochester, Minn.

   The purpose of this research study is testing a new technique for measuring stiffness of the lung. This new technique is called Magnetic Resonance Elastography (MRE). In this study we will look at the stiffness measurements in humans.

8. Ferromagnetic Detection of Cardiac Devices using a Metrasens Screener

   Rochester, Minn.

   The purpose is to conduct a study that determines the efficiency of FMDS in pre MRI screening for detecting cardiac implants in a Mayo Clinic environment.

9. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients

   Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients.